71 related articles for article (PubMed ID: 35580321)
1. Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity.
Okazaki E; Barion BG; da Rocha TRF; Di Giacomo G; Ho YL; Rothschild C; Fatobene G; de Carvalho Moraes BDG; Stefanello B; Villaça PR; Rocha VG; Orsi FA
J Thromb Thrombolysis; 2024 Apr; 57(4):721-729. PubMed ID: 38523179
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies.
Perl M; Herfeld K; Harrer DC; Höpting M; Schweiger M; Sterz U; Knödler L; Heimerl S; Hansmann L; Herr W; Poeck H; Wolff D; Edinger M; Hart C; Fante MA
Haematologica; 2024 Mar; ():. PubMed ID: 38546698
[TBL] [Abstract][Full Text] [Related]
3. Tisagenlecleucel in Diffuse Large B-Cell Lymphoma.
Geoffrion D; Whittaker H
N Engl J Med; 2019 Apr; 380(16):1585. PubMed ID: 30995382
[No Abstract] [Full Text] [Related]
4. Tisagenlecleucel in Diffuse Large B-Cell Lymphoma.
Schwartz JD
N Engl J Med; 2019 Apr; 380(16):1585-1586. PubMed ID: 30995383
[No Abstract] [Full Text] [Related]
5. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells.
Galli E; Sorà F; Hohaus S; Fresa A; Pansini I; Autore F; Metafuni E; Innocenti I; Limongiello MA; Giammarco S; Laurenti L; Bacigalupo A; Chiusolo P; De Stefano V; Sica S
Br J Haematol; 2023 Apr; 201(1):86-94. PubMed ID: 36503182
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia.
Guarini A; Radice G; Peragine N; Buracchi C; De Propris MS; Di Rocco A; Di Rocco A; Chiaretti S; Moretti A; Napolitano S; Martelli M; Balduzzi A; Gaipa G; Biondi A; Foà R
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173879
[No Abstract] [Full Text] [Related]
9. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
Ahmed N; Wesson W; Mushtaq MU; Porter DL; Nasta SD; Brower J; Bachanova V; Hu M; Nastoupil LJ; Oluwole OO; Patel VG; Oliai C; Riedell PA; Bishop MR; Shah GL; Perales MA; Schachter L; Maziarz RT; McGuirk JP
Transplant Cell Ther; 2023 Jul; 29(7):449.e1-449.e7. PubMed ID: 37120134
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
11. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.
Cuffel A; Allain V; Faivre L; Di Blasi R; Morin F; Vercellino L; Chevalier MF; Desnoyer A; de Jorna R; Madelaine I; Parquet N; Brignier AC; Thieblemont C; Larghero J; Caillat-Zucman S; Mebarki M
Blood Adv; 2022 Aug; 6(15):4657-4660. PubMed ID: 35728051
[No Abstract] [Full Text] [Related]
12. Cardiovascular toxicities associated with bispecific T-cell engager therapy.
Sayed A; Munir M; Ghazi SM; Ferdousi M; Krishan S; Shaaban A; Habib A; Kola-Kehinde O; Ruz P; Khan S; Sharma S; Meara A; Mahmood S; Feldman S; Yang EH; Kim J; Epperla N; Addison D
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38388168
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy.
Yoshida M; Matsuoka Y; Mitsuyuki S; Yonetani N; Kawai J; Kondo T; Ishikawa T
Blood Cell Ther; 2023 Nov; 6(4):129-134. PubMed ID: 38149020
[TBL] [Abstract][Full Text] [Related]
14. IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy.
Wang X; Li C; Luo W; Zhang Y; Huang Z; Xu J; Mei H; Hu Y
Ann Hematol; 2023 Dec; 102(12):3575-3585. PubMed ID: 37814134
[TBL] [Abstract][Full Text] [Related]
15. Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma.
Yamasaki-Morita M; Arai Y; Ishihara T; Onishi T; Shimo H; Nakanishi K; Nishiyama Y; Jo T; Hiramatsu H; Mitsuyoshi T; Mizumoto C; Kanda J; Nishikori M; Kitawaki T; Nogami K; Takaori-Kondo A; Nagao M; Adachi S
Blood Adv; 2022 Jul; 6(14):4216-4223. PubMed ID: 35580321
[TBL] [Abstract][Full Text] [Related]
16. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
Chen HH; Kuo CY; Ho CL; Chen YC
Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
[TBL] [Abstract][Full Text] [Related]
17. [Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].
Hanajiri R; Furukawa K; Nakashima M; Ushijima Y; Shimada K; Ishikawa Y; Terakura S; Murata M; Kiyoi H
Rinsho Ketsueki; 2023; 64(3):167-174. PubMed ID: 37019669
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
19. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
